MedPath

Ultrasound Guided Versus Surgical Rectus Sheath Block Versus Local Anesthesia Infiltration for Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy

Not Applicable
Recruiting
Conditions
Ultrasound
Rectus Sheath Block
Surgical
Local Anesthesia Infiltration
Postoperative Analgesia
Total Abdominal Hysterectomy
Interventions
Drug: Ultrasound-guided rectus sheath block
Drug: Surgical rectus sheath block
Drug: Local anesthesia infiltration
Registration Number
NCT06837532
Lead Sponsor
Ain Shams University
Brief Summary

The aim of this work is to compare the efficacy and safety of the effectiveness and safety of ultrasound-guided surgical rectus sheath block and local anesthetic infiltration for postoperative analgesia in patients undergoing total abdominal hysterectomy.

Detailed Description

Total abdominal hysterectomy (TAH) is a commonly performed major surgical procedure that results in substantial postoperative pain and discomfort.

Local anesthetic infiltration (LAI) at the end of surgery is one of the most common technique employed in laparotomies for postoperative analgesia.

Rectus sheath block (RSB) has been used as a part of multimodal analgesia, especially when neuraxial techniques are unsuitable.The RSB was used to achieve peri-operative relaxation of the anterior abdominal wall.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
90
Inclusion Criteria
  • Age from 18 to 65 years old.
  • American Society of Anesthesiologists (ASA) physical status I - II.
  • Patients scheduled for elective total abdominal hysterectomy under general anesthesia.
Exclusion Criteria
  • Hepatic, renal or cardiac disease.
  • Any known allergy to local anesthetic.
  • Physical or mental conditions which may vaguely measure postoperative pain following surgery.
  • History of chronic use of analgesic as nonsteroidal anti-inflammatory drugs (NSAIDs) or central nervous system (CNS) depressants as antiepileptic, and bleeding disorders.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ultrasound-guided rectus sheath block groupUltrasound-guided rectus sheath blockPatients will receive ultrasound-guided rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the end of surgery.
Surgical rectus sheath block groupSurgical rectus sheath blockPatients will receive a surgical rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the time of closure.
Local anesthesia infiltration groupLocal anesthesia infiltrationPatients will receive local anesthesia infiltration at the end of surgery.
Primary Outcome Measures
NameTimeMethod
Total morphine consumption24 hours postoperatively

Rescue analgesia of morphine will be given as 3 mg bolus if the Visual Analogue Scale (VAS)\> 3 to be repeated after 30 min if pain persists until the VAS \< 4.

Secondary Outcome Measures
NameTimeMethod
Heart rateTill the end of surgery (Up to 4 hours)

Heart rate will be recorded preoperatively, before the block is performed, and every 15 minutes until the end of the surgery.

Mean arterial pressureTill the end of surgery (Up to 4 hours)

Mean arterial pressure will be recorded preoperative, before performing of block, and every 15 min till the end of surgery.

Time to the first request for the rescue analgesia24 hours postoperatively

Time to the first request for the rescue analgesia (time from end of surgery to first dose of morphine administrated).

Degree of pain24 hours postoperatively

Each patient will be instructed about postoperative pain assessment with the Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS will be assessed at PACU, 2, 4, 6, 12, 18, and 24h postoperatively.

Degree of patient satisfaction24 hours postoperatively

Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).

Incidence of adverse events24 hours postoperatively

Incidence of adverse events such as hematoma, nerve damage or neuropathy, bradycardia, hypotension, nausea, vomiting, pruritis, urinary retention, or any other complication will be recorded.

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Egypt

Ain Shams University
🇪🇬Cairo, Egypt
Sarah A Afifi, MD
Contact
0501035864
Sarah606060@gmail.com
Sondos Afifi, MD
Principal Investigator
Ahmed Eldemerdash, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.